Literature DB >> 21081787

The biologic spectrum of thymic epithelial neoplasms: current status and future prospects.

Richard T Cheney1.   

Abstract

Thymoma is the most common anterior mediastinal tumor in adults and is frequently associated with autoimmune disorders such as myasthenia gravis. Thymomas are a diverse group of epithelial neoplasms with a behavioral spectrum that spans the complete clinical gamut from entirely benign to highly aggressive, lethal thymic carcinomas. The biologic behavior seems to depend primarily on the clinical stage at presentation and histologic subtype. This article discusses thymic organogenesis, Masaoka staging, WHO histologic classification of thymoma and thymic carcinoma, and selected molecular characteristics that highlight this diversity. This discussion will further underscore both the similarities and differences between categories of thymic epithelial neoplasms and offer support for the notion that tumor heterogeneity and/or tumor progression may explain the observed clinical variation in behavior. Recommendations are offered for future investigational approaches to further the understanding of the complexity of these tumors.

Entities:  

Mesh:

Year:  2010        PMID: 21081787     DOI: 10.6004/jnccn.2010.0097

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  4 in total

1.  Treatment updates in advanced thymoma and thymic carcinoma.

Authors:  Matthew A Gubens
Journal:  Curr Treat Options Oncol       Date:  2012-12

2.  Thymoma in myasthenia gravis: from diagnosis to treatment.

Authors:  Fredrik Romi
Journal:  Autoimmune Dis       Date:  2011-08-10

Review 3.  Myasthenia gravis associated with invasive malignant thymoma: two case reports and a review of the literature.

Authors:  Said R Beydoun; Hui Gong; Nazely Ashikian; Richard Alan Rison
Journal:  J Med Case Rep       Date:  2014-10-13

4.  Case Report of Thymoma Tumor Reduction Following Plasmapheresis.

Authors:  Wei Jiang; Qitao Yu
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.